- Traitement Anticancereux, Fonction de Reproduction et Sexualtite
- Published:
Protection gonadique contre les effets des chimiothérapies et/ou radiothérapies chez l'homme: applications cliniques
Protection of the testis against side effects of cancer therapy: clinical trials
Andrologie volume 5, pages 504–511 (1995)
Resume
Les effets délétères des chimiothérapies et radiothérapies sur la spermatogenèse touchent des hommes jeunes en âge de procréer. Au delà de l'autoconservation de sperme obligatoire avant la mise en route du traitement anticancéreux, des protocoles ayant pour objectifs de protéger la spermatogenèse pourraient être proposés chez l'homme. Les analogues du GnRh ou les stéroïdes ont été utilisés dans ce but chez l'homme. Cette revue bibliographique résume les différentes études publiées et en discute les limites. A la lumière des travaux expérimentaux réalisés chez l'animal et de la mise au point de nouvelles molécules, des perspectives de protection de la spermatogenèse sont proposées.
Abstract
The damage effects of cytotoxic chemotherapy or radiotherapy were particularly important on spermatogenesis and fertility of young patients who were treated for cancer. The cryopresevation of semen is obligatory in these patients before starting therapy. In animals several protosols have been tried to protect the testis against chemotherapy and radiotherapy with positive results. In men, seven clinical trials have been done to preserve the testis by means of hormonal treatment. Five used GnRh agonist, one medroxyprogesterone acetate and the last one testosterone enanthate. These patients where treated with chemotherapy or/and radiotherapy. None of these clinical trials had any protective effect on testis function. The results of these studies, and the reasons of this failure are discussed, and, based on animals experiments and recent drogues availability new protosols of spermatogenesis preservation are suggested such as use of steroids, GnRh antagonist or testis hypothermia.
References
BASTIAS M.C., KAMIJO H., PAVLOW S.N.: Sperm motion parameters after suppression of spermtogenesis with a GnRh antagonist plus testosterone supplementation. Fertil. Steril. 1993, 59: 1261–1265.
FOSSA S.D., KLEPP O., NORMAN N.: lack of gonadal protection by medroxyprogesterone acetate-induced transient medical castration during chemotherapy for testicular cancer. Br. J. Urol., 1988, 62 (5): 449–453.
HOLLARD D., SOTTO J.J., BERTHIER R. et al.: High rate of long-term survivals in AML treated by chemotherapy and androgenotherapy. Cancer, 1980, 45: 1540–1548.
JEGOU B., VELEZ DE LA CALLE and BAUCHE F.: Protective effect of medroxyprogestérone acetate plus testostérone against radiation induced damage to the productive function of male rats and their offspring. Proc. Natl. Acad. Sci. 1991, 88: 8710–8714.
JOHNSON D.H., LINDE R., HAINSWORTH J.D. et al.: Effect of a Luteinizing Hormone Releasing Hormone agonist given du ring combination chemotherapy on post-therapy fertility in male patients with lymphoma: preliminary observations. Blood, 1985, 65, 4: 832–836.
KLINGMULLER D.: Protection of radiation-induced gonadal failure by D-try-6LHRH; in: Klingmuller D., Wildt E. (Eds): GnRH-analogues in therapy. Thieme Verlag, Stuttgart, 1993.
KRAUSE W. And PFLUGER K.H.: Treatment with the gonadotropin-releasing hormone agonist Buserelin to protects spermatogenesis against cytotoxic treatment in young men. Andrologia, 1989, 21 (3): 265–270.
KREUSER E.D., HETZEL W.D., HARTMANN R., PFEIFFER E.F.: Reproductive toxicity with and without LHRHA administration during adjvant chemotherapy in patients with germ cell tumors. Horm. Metab. Res. 1990, 22: 494–498.
MEISTRICH M.: Mecanismes de la protection gonadique par les hormones. Communication à la table ronde organisée par le groupe PROSPERM: la protection gonadique: de l'expérimentation animale à la clinique. Paris 17 mars 1993.
MULCAHY J.J.: Scrotal hypothermia and the infertile men. J. Urol. 1984, 132: 469–470.
PAVLIDIS N., NIKOLAOU N., TOLIS Ch. et al.: is androgen substitution necessary in hypogonadal patients when they are treated with chemotherapy for malignant diseases. Med. Pediat. Oncol. 1989, 17: 222–226.
ROBINSON D., ROCK J.: Controle of human spermatogenesis by induced changes of intrascrotal temperature. JAMA, 1968, 204, 4: 80–87.
TOM L., BHASIN S., SALAMEH W. et al.: Induction of azoospermia in normal men with combined Nal-glu GnRh antagonist and testostérone enanthate. J. Clin. Endocrinol. Metab. 1992, 75: 476–483.
VAN ALPHEN M.M.A., VAN DE KANT H.J.G., DE ROOIJ D.G.: Protection from radiation-induced damage of spermatogenesis in the rhesus monkey (Macaca mulate) by FSH. Cancer Res. 1989, 49: 53.
VELEZ de la CALLE J.F., BAUCHE F., JEGOU B.: Protection de la fertilité male lors des traitements anticancéreux: I'expérience animale. Prog. Urol., 1992, 2: 110–112.
VELEZ de la CALLE J.F., BEN HASSEL M., JEGOU B.: Protection gonadique contre les effets iatrogènes des traitements anticancéreux: données expérimentales. Andrologie, 1995, ce numéro.
VELEZ de la CALLE J.F., BEN HASSEL M., JEGOU B.: Hypothermia protects rat spermatogenesis against a sterilizing dose of gamma rays. 85 th Annual Meeting of the Am. Ass. Cancer. Res. San Francisco: 1994, April 10–13.
WAXMAN J.H., AHMED R., SMITH D. et al.: Failure to preserve fertility in patients with Hodgkin's disease. Cancer Chemother. Pharmacol., 1987, 19: 159.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bujan, L., Mieusset, R. Protection gonadique contre les effets des chimiothérapies et/ou radiothérapies chez l'homme: applications cliniques. Androl. 5, 504–511 (1995). https://doi.org/10.1007/BF03034535
Issue Date:
DOI: https://doi.org/10.1007/BF03034535